Revolutionizing the Way the Body Responds to Injury
Xequel’s proprietary aCT1 peptide technology platform has extensive preclinical and clinical research to support multiple unique applications and formulations across therapeutic areas. We are committed to developing treatments that address unmet medical needs and revolutionize the way the body responds to injury.
Preclinical
IND Enabling
Phase 1
Phase 2
Phase 3
Dermatology
Cutaneous Radiation Injury (CRI)
Revolutionizing the Way the Body Responds to Injury
Xequel’s aCT1 technology platform is designed to stimulate healing by creating an improved injury response. Our proprietary aCT1 technology restores the gap junctions to normalize cell-to-cell signaling and facilitate proper healing.
